A more recent prospective randomized double-blind trial in CKD patients undergoing HD found that supplementation with 2.4 g/d of ω-3 PUFA for 12 weeks significantly lowered the levels of inflammatory markers such as CRP, interleukin-6 (IL-6), and tumor necrosis factor α (TNFα) [97]. The gene discussed is IL6; the disease is chronic kidney disease.